Dear Doctor - Participate in the Survey on hepatitis of unknown etiology " A recent survey of hepatitis cases of unknown etiology in children found that the vast majority of cases were in infants under the age of 6 months. The most common symptoms reported were fever, diarrhea, and vomiting. However, a small number of children also had jaundice and liver enzymes that were elevated. The most common tests used to diagnose hepatitis are the alanine aminotransferase (ALT) test and the aspartate aminotransferase (AST) test. These tests can be used to identify liver damage and determine the cause of the hepatitis. In some cases, additional testing, such as a viral load test or a liver biopsy, may be needed to confirm the diagnosis. Treatment for hepatitis usually involves supportive care, such as rest and fluids, and may also include medications to reduce liver inflammation or suppress the immune system. Participate in Surveys "
1.
enhancing survivors of brain tumors' quality of life.
2.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
3.
A protein with new anticancer activity has been identified
4.
Studies point to redlining as a 'perfect storm' for breast cancer
5.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care
3.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
4.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
5.
Progressive Strategies in Oncology and Patient Outcomes
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
Managing Common Side Effects During Cancer Treatment
5.
Clinical Insights in Oncology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation